CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer with a poor prognosis and limited treatment options. Considering that alterations of the CDK4/6-cyclin D-Rb pathway occur frequently in HCC, we tested the efficacy of two CDK4/6 inhibitors, abemaciclib and ribociclib, in combin...

Descripción completa

Detalles Bibliográficos
Autores principales: Digiacomo, Graziana, Fumarola, Claudia, La Monica, Silvia, Bonelli, Mara, Cavazzoni, Andrea, Galetti, Maricla, Terenziani, Rita, Eltayeb, Kamal, Volta, Francesco, Zoppi, Silvia, Bertolini, Patrizia, Missale, Gabriele, Alfieri, Roberta, Petronini, Pier Giorgio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354684/
https://www.ncbi.nlm.nih.gov/pubmed/35936714
http://dx.doi.org/10.3389/fonc.2022.942341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9354684/
https://www.ncbi.nlm.nih.gov/pubmed/35936714
http://dx.doi.org/10.3389/fonc.2022.942341

Ejemplares similares